Changes in insulin utilization in China from 2020 to 2022
Authors' conclusion
From 2020 to 2022, the procurement of insulin increased, which may be due to the increased attention for diabetes from the country and residents.However, the proportion of insulin among all antidiabetic medicines was essentially unchanged, while the use of some non-insulin hypoglycemic drugs increased significantly, especially the SGLT2i and GLP-1 RA. Given the economic and cultural diversity, Insulin procurement and utilization patterns varied greatly across the regions. Owning domestic enterprises potentially influences the procurement of insulin. Enhancing education to further improve the self-management of patients with diabetes is essential.
Study context
- Population
- Insulin and other antidiabetic medicine procurement across China, 2020–2022
- Outcome
- Antidiabetic medicine and insulin procurement
- Follow-up
- 2020 to 2022
Methodological detailsnational procurement data, defined daily doses, seven regions, multifactor linear regression
- National procurement data
- Defined daily doses
- Seven regions
- Multifactor linear regression
Main finding
As reported in the abstract
Proportion of insulin among antidiabetic medicines remained stable
≈22%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →